Global Alpha 1 Antitrypsin Deficiency Treatment Market to Reach US$ 4.0 Billion by 2032, Augmented by Increasing Prevalence of Chronic Respiratory Diseases

September 30, 2020 | Healthcare

According to the latest report by IMARC Group, titled “Alpha 1 Antitrypsin Deficiency Treatment Market Report by Treatment Type (Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, and Others), Route of Administration (Parenteral, Inhalation, Oral), End User (Hospitals, Specialty Clinics, and Others), and Region 2024-2032,” the global alpha 1 antitrypsin deficiency treatment market reached a value of US$ 2.0 Billion in 2023. Alpha 1 antitrypsin deficiency (AAT) is an inherited condition wherein the body fails to produce an adequate amount of AAT, a protein that protects the lungs and liver from the harmful effects of other proteins. Its deficiency often leads to liver cirrhosis, emphysema diseases and chronic obstructive pulmonary diseases (COPD). Some of its common symptoms include tiredness, vision problems, weight loss, shortness of breath, repeated lung infections and rapid heartbeat on standing. AAT deficiency is nowadays treated using different therapeutic methods, such as corticosteroids, oxygen therapy, bronchodilators and augmentation therapy.

Global Alpha 1 Antitrypsin Deficiency Treatment Market Trends:

The global market is presently experiencing growth on account of the rising cases of the alpha 1 antitrypsin deficiency and the increasing prevalence of chronic respiratory diseases. Besides this, technological advancements in diagnostic methods, along with the development of innovative processes for the production and purification of AAT, are positively influencing the demand for the treatment. Furthermore, the increasing expenditure on research and development (R&D) in asthma and chronic obstructive pulmonary disease (COPD) treatment, in confluence with the growing number of awareness programs, is propelling the growth of the market. However, the sudden spread of the coronavirus disease (COVID-19) and lockdowns imposed by governments of numerous countries have negatively influenced the market growth on account of temporary disturbances caused in the supply chain and operations of manufacturing units. The market is expected to experience growth once normalcy is regained. Looking forward, the market value is projected to reach US$ 4.0 Billion by 2032, expanding at a CAGR of 7.6% during the forecast period (2024-2032).

Market Summary:

  • Based on the treatment type, the market has been segmented into augmentation therapy, bronchodilators, corticosteroids, oxygen therapy and others.
  • On the basis of the route of administration, the market has been segregated into parenteral, inhalation and oral.
  • The market has been analyzed on the basis of the end user into hospitals, specialty clinics and others.
  • Region-wise, the market has been divided into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others); Europe (the United Kingdom, Germany, France, Italy, Spain, Russia and others); Latin America (Brazil, Mexico and others); and Middle East and Africa.
  • The competitive landscape of the market has been examined, with some of the key players being AstraZeneca PLC, C.H. Boehringer Sohn AG & Ko. KG, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments S.A., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Treatment Type, Route of Administration, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered AstraZeneca PLC, C.H. Boehringer Sohn AG & Ko. KG, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments S.A., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Alpha 1 Antitrypsin Deficiency Treatment Market to Reach US$ 4.0 Billion by 2032, Augmented by Increasing Prevalence of Chronic Respiratory Diseases
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-713-2163


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More